Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
Alamar Biosciences (Nasdaq: ALMR) said its NULISA platform will be featured in more than 140 poster and session presentations at AAIC 2026 in London (July 12-15). The company plans a workshop on July 14 highlighting new eMTBR-Tau and BD-pTau217 data, including results from a single NULISAseq panel measuring these assays alongside 220+ proteins.
How this was made
The 30-second read
Why it matters
The article highlights expanded multiplex profiling (eMTBR-Tau and BD-pTau217) and claims improved discrimination versus single-analyte pTau-217, but it does not provide quantitative results, study endpoints, or regulatory/commercial milestones.
Market read
Signals continued research adoption and expanded assay positioning for Alzheimer’s blood-based diagnostics, but lacks new decision-grade financial or regulatory catalysts.
What to watch
Traders may be over-weighting multiplex assay promise without evidence of assay reproducibility across cohorts, payer/clinical adoption, or any announced partnerships, reimbursement pathways, or regulatory submissions.
Background
Alamar Biosciences is promoting its NULISA platform and ARGO HT system for blood-based precision proteomics, with a focus on Alzheimer’s tau and related biomarkers.
Ticker impact
Alamar says its NULISA platform will be featured in 140+ AAIC 2026 presentations, highlighting new eMTBR-Tau and BD-pTau217 multiplex data.
Near-term impact likely limited to sentiment, with follow-through depending on any subsequent trial, validation, or commercial updates.
The article is a press-release style conference preview and does not include new trial outcomes, FDA/CLIA milestones, contracts, or financial guidance. The only concrete incremental details are the specific assays (eMTBR-Tau, BD-pTau217) and the scale of AAIC presentations.
Market effects
Reinforces the broader proteomics and blood-based Alzheimer biomarker narrative, but does not change competitive benchmarks with hard new performance or regulatory outcomes.
No clear regional market linkage beyond the London conference setting.
Moderate relevance for global Alzheimer diagnostics research community; limited direct market impact without clinical or regulatory milestones.
Counterpoint
Conference participation and poster counts may reflect marketing and research interest rather than validated clinical utility or near-term revenue conversion.
Key entities
- public_companyAlamar Biosciences, Inc.
Nasdaq-listed precision proteomics company promoting NULISA and ARGO HT for Alzheimer’s biomarker profiling.
- technologyNULISA™ platform
Alamar’s multiplex protein profiling platform used for blood-based Alzheimer’s biomarker assays.
- producteMTBR-Tau and BD-pTau217 assays
Alamar assays highlighted as specific blood-based indicators and featured in AAIC 2026 presentations.
- eventAAIC 2026 (Alzheimer’s Association International Conference)
July 12-15 conference in London where Alamar will present workshop and posters.


